Larimar Therapeutics stock plunges after FDA halts clinical trial
Larimar Therapeutics' stock plummeted by more than 33% Wednesday after the U.S. Food and Drug Administration halted the Bala Cynwyd company's clinical development of its lead new drug candidate.
The FDA put a clinical hold on trials of CTI-1601, Larimar's experimental therapy for Friedreich’s ataxia, following the company's previous notification to the federal agency concerning mortalities which occurred at the highest dose levels in an ongoing 180-day non-human primate toxicology study .
In…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: John George Source Type: news
More News: American Health | Ataxia | Clinical Trials | Food and Drug Administration (FDA) | Health Management | Study | Toxicology